GLP-1 medications such as Wegovy, Zepbound, semaglutide, and tirzepatide have helped many patients lose a meaningful amount of weight. I prescribe and supervise medical weight loss treatment, and I have seen these medications work very well for the right patient.

But I have also seen the other side.

Some patients lose weight, then regain it when insurance stops covering the medication. Others cannot tolerate the dose they need. Some stop because of side effects, cost, supply issues, or the reality that they do not want to take an injectable medication indefinitely.

That is why more patients are searching for information about GLP-1 long-term results, weight regain after Wegovy, weight regain after Zepbound, and whether gastric sleeve surgery or gastric bypass surgery may be a more durable option.

GLP-1 Medications Work—But They Are Almost Always Going to Have to be a Long-Term Treatment

One of the most important points patients need to understand is that obesity is a chronic disease. It is not simply a willpower problem, and it is not solved by one short burst of effort.

Body weight is influenced by appetite hormones, genetics, metabolism, medications, sleep, stress, insulin resistance, food environment, activity level, and many other factors. When a patient loses weight, the body often responds by increasing hunger and lowering energy expenditure. That is one reason weight regain is so common after dieting alone.

GLP-1 medications help by changing appetite signaling, improving fullness, slowing stomach emptying, and improving glucose regulation. For many patients, that can make it much easier to eat less and lose weight.

The problem is that these benefits often depend on continuing the medication. When the medication is stopped, appetite frequently returns.

What Recent Data Show About GLP-1 Long-Term Results

The clinical trials for semaglutide and tirzepatide showed impressive weight loss results. But clinical trials are not the same as real life.

In real-world practice, patients often stop treatment, use lower doses, or lose coverage. That changes the long-term outcome.

A Cleveland Clinic real-world study of nearly 7,900 adults treated with semaglutide or tirzepatide found that weight loss was much lower in routine practice than in clinical trials, largely because many patients discontinued treatment or stayed on lower maintenance doses. More than 20% discontinued within the first 3 months, and another 32% discontinued between 3 and 12 months. At 1 year, average weight loss was about 3.6% for early discontinuers, 6.8% for later discontinuers, and 11.9% for patients who continued treatment. Patients who stayed on higher doses did better. Read the Cleveland Clinic summary.

That finding lines up with what many obesity medicine practices see: GLP-1s can work very well, but the long-term result depends heavily on access, adherence, tolerability, and dose.

What Happens When Patients Stop Wegovy or Zepbound?

The best-known semaglutide withdrawal data come from the STEP 1 extension study. Patients who had been treated with semaglutide lost an average of 17.3% of body weight during treatment. After stopping semaglutide, they regained 11.6 percentage points of that lost weight by week 120, leaving a net loss of only 5.6% from baseline. View the STEP 1 extension study on PubMed.

In plain English: many patients regained a large portion of the weight they had lost after stopping the medication.

A 2026 BMJ systematic review found a similar pattern across weight-management medications. After stopping medication, patients tended to regain weight and lose some of the cardiometabolic improvements they had achieved during treatment. The review concluded that stopping weight-management medication was followed by rapid weight regain, especially without a comprehensive long-term obesity treatment plan. Read the BMJ review.

Why GLP-1 Weight Regain Happens

Patients sometimes feel embarrassed when they regain weight after stopping Wegovy or Zepbound. They should not.

Weight regain after stopping GLP-1 medications is not a character flaw. It is biology.

When GLP-1 Medications May Be a Good Fit

GLP-1 medications can be a very reasonable option for many patients.

They may be a good fit for a patient who:

• Has obesity or overweight with weight-related medical problems.
• Wants a non-surgical treatment.
• Has insurance coverage or can afford long-term treatment.
• Tolerates the medication well.
• Is comfortable with ongoing medication use.
• Has a plan for nutrition, activity, protein intake, and follow-up.
• Needs help with appetite control before or after bariatric surgery.

At JourneyLite, we offer medical weight loss and GLP-1 treatment pathways for appropriate patients. I do not view medication as “less serious” than surgery. Obesity medicine is real medicine, and medication can be an important tool.

The question is whether it is the right long-term tool for a specific patient.

When Gastric Sleeve or Gastric Bypass May Be a Better Long-Term Option

For patients with more severe obesity, repeated weight regain, type 2 diabetes, sleep apnea, high blood pressure, joint pain, or a long history of unsuccessful dieting, bariatric surgery may offer a more durable treatment.

Gastric sleeve and gastric bypass work differently than GLP-1 medications. They do not simply reduce willpower demands. They change hunger, fullness, gut hormone signaling, portion tolerance, and metabolic function.

At JourneyLite Surgery Center in Cincinnati, we specialize in outpatient bariatric surgery, including gastric sleeve, gastric bypass, revisional bariatric surgery, and lap band management. We have been helping patients with weight loss since 2008 and serve patients from Cincinnati, Dayton, Columbus, Northern Kentucky, Indiana, Indianapolis, and beyond.

A 2025 Cleveland Clinic study published in Nature Medicine compared metabolic surgery with GLP-1 receptor agonist treatment in patients with obesity and type 2 diabetes. The study found that surgery was associated with greater long-term weight loss and lower risks of several major health outcomes, including all-cause mortality, compared with GLP-1 medication alone. Read the Nature Medicine study.

At JourneyLite, we are direct about these realities. Bariatric surgery is powerful, but it is not magic. It is a tool that works best with experienced surgical care, dietitian support, realistic expectations, and long-term follow-up.

Surgery and GLP-1 Medications Are Not Always Competitors

One of the biggest mistakes in obesity treatment is framing the decision as “medication versus surgery” for every patient.

Sometimes the best answer is medication. Sometimes the best answer is surgery. Sometimes the best answer is both.

For example, a patient may use a GLP-1 medication before surgery to lower operative risk. Another patient may have gastric sleeve surgery and later use a GLP-1 medication for weight regain or increased appetite years later. A patient with very high BMI may need a staged plan. A patient who is not ready for surgery may start with medical weight loss or a gastric balloon.

The best obesity treatment plan is individualized.

Practical Examples: Which Patient May Fit Which Treatment?

The Bottom Line on GLP-1 Long-Term Results

GLP-1 medications are valuable obesity treatment tools. Wegovy, Zepbound, semaglutide, and tirzepatide can produce meaningful weight loss for many patients.

But recent data show several important limitations:

• Real-world results are often less dramatic than clinical trial results.
• Many patients discontinue treatment within the first year.
• Lower doses may produce less weight loss.
• Weight regain is common after stopping medication.
• Long-term success often requires long-term treatment.
• Patients with severe obesity may need a more durable option.

As a bariatric surgeon and obesity medicine physician, my advice is simple: do not choose a treatment based only on what is popular right now. Choose the treatment that matches your medical history, BMI, weight-loss goals, risk tolerance, insurance situation, and ability to follow through long term.

About the Author

Trace Curry, MD, FASMBS is the founder and Medical Director of JourneyLite Physicians and JourneyLite Surgery Center in Cincinnati, Ohio. He is a bariatric surgeon and obesity medicine physician with extensive experience in gastric sleeve, gastric bypass, revisional bariatric surgery, gastric balloon procedures, lap band management, GLP-1 medications, and non-surgical medical weight loss.

Since 2008, JourneyLite has helped patients throughout Ohio, Kentucky, Indiana, and beyond choose individualized treatment plans for long-term obesity care.

Learn more about Dr. Trace Curry